Share

European Health Stakeholder Group Statement on the UK data protection regime

The European Health Stakeholder Group welcomes the decision on the UK data protection regime issued by the Article 93 Committee on 17 June.

EU Member States voted unanimously in favour to approve the adequacy decision which means that the flow of personal data from the EU to the UK will continue uninterrupted post-Brexit.

With just 13 days to go until the interim EU-UK data sharing agreement expires, the entire European healthcare sector can breathe a sigh of relief.

Recognition of UK data adequacy is vital for the functioning of the European health sector. It determines everything from the delivery of cross border health and social care for thousands of European citizens, to governing how health data is securely shared to advance research.

This result addresses the many and significant concerns we raised with key UK and EU decision-makers on behalf of members and the healthcare sector. Without an adequacy decision, health data flows would have stopped suddenly on 30 June unless organisations had alternative transfer mechanisms in place. The impact of this would have been felt across the entire healthcare sector, without exception and during a global pandemic.

With this decision, the EU and UK can continue to benefit from the continued secure flow of personal data to facilitate the development of new treatments and to improve patient safety and care across Europe.

It is now important that the decision is implemented before the 30 June deadline to ensure continuity in EU-UK data sharing.

Back to news list

Related News

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023

  • EORTC Quality of Life measures integrated in CDISC

  • EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma

  • Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia

  • New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023